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Abstract: The treatment of high-risk prostate cancer (HRPCa) is a tremendous challenge 
for uro-oncologists. The identification of predictive moleculobiological markers allowing 
risk assessment of lymph node metastasis and systemic progression is essential in 
establishing effective treatment. In the current study, we investigate the prognostic 
potential of miR-205 in HRPCa study and validation cohorts, setting defined clinical 
endpoints for both. We demonstrate miR-205 to be significantly down-regulated in over 
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70% of the HRPCa samples analysed and that reconstitution of miR-205 causes inhibition 
of proliferation and invasiveness in prostate cancer (PCa) cell lines. Additionally, miR-205 
is increasingly down-regulated in lymph node metastases compared to the primary tumour 
indicating that miR-205 plays a role in migration of PCa cells from the original location 
into extraprostatic tissue. Nevertheless, down-regulation of miR-205 in primary PCa was 
not correlated to the synchronous presence of metastasis and failed to predict the outcome 
for HRPCa patients. Moreover, we found a tendency for miR-205 up-regulation to 
correlate with an adverse outcome of PCa patients suggesting a pivotal role of miR-205 in 
tumourigenesis. Overall, we showed that miR-205 is involved in the development and 
metastasis of PCa, but failed to work as a useful clinical biomarker in HRPCa. These 
findings might have implications for the use of miR-205 as a prognostic or therapeutic 
target in HRPCa. 
Keywords: high-risk prostate cancer; microRNA; miR-205; prognosis; biomarker 
 
1. Introduction 
High-risk prostate cancer (HRPCa, defined by Gleason score ≥ 8 and/or pT ≥ 3 and/or  
PSA ≥ 20 ng/µL) is a PCa subgroup with varying risk of biochemical progression (BCR), clinical 
failure (CF) and cancer-specific mortality (CSM) following radical prostatectomy [1]. Today,  
uro-oncologists are faced with the complex decision about the type and timing of primary  
treatment [2]. While the key event of lymph node metastasis, which often remains undiscovered prior 
to initial treatment, impacts significantly upon management, reliable preoperative detection with 
current diagnostic imaging remains unsatisfactory [3].  
Thus, new prognostic markers for HRPCa are necessary, especially if therapeutic targets are to be 
met. Numerous potential prognostic biomarkers have been identified but none of these has entered 
broader clinical use yet [4]. Among moleculobiological markers, the more recently described non-coding 
microRNAs (miRs) show promising results [5]. MiRs are small RNAs (19–25 nt long) regulating gene 
expression by binding to mRNA sequences and repressing target gene expression post-transcriptionally, 
either by inhibiting translation or by promoting RNA degradation [6]. Alterations of miR expression 
were detected in various cancer entities including PCa [7–14]. Functional studies have shown miRs to 
either function as tumour suppressors or oncogenes depending on the modulation of different target 
genes [8]. In addition, miR expression profiles stratify cancers by clones and level of differentiation 
suggesting that miRs are involved in cancer progression [9,10].  
However, understanding the regulation and function of miRs in normal and neoplastic tissues 
remains a great challenge. Recent studies of several miRs exhibited both positive and negative 
correlation between expression and tumour type implicating a very complex and dynamic function of 
miRs for tumour development and progression [8–10]. Also, miR-205 either acts as a tumour 
suppressor or as an oncogene depending on the regulation of potential target genes in the context of the 
specific tumour [15,16] It has been shown that miR-205 is frequently down-regulated in a variety of 
cancer entities and its tumour-suppressive action is well studied [17–27]. MiR-205 impacts crucial 
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pathways involved in proliferation, invasion and angiogenesis by mediating the expression of multiple 
oncogenes like HER3, VEGF-A, or MED1 [20,21,27]. Further important pathways in cancerogenesis 
regulated by miR-205 are NFKβ-enhancing, epithelial to mesenchymal transition (EMT) and induction 
of chemotherapy resistance [23–27]. In contrast to this tumour-suppressive function of miR-205, 
several studies have described miR-205 as up-regulated in lung cancer or HNSCC (head and neck cell 
squamous carcinoma) suggesting an oncogenic role [28,29]. The oncogenic function of miR-205 is 
substantiated by suppression of potential tumour-suppressor genes like PTEN, TRAF2 or SHIP2 and by 
promotion of aggressive lung and squamous carcinomas [28–31]. 
With regard to PCa, miR-205 has been reported to be frequently down-regulated and it was suggested 
that down-regulation might be associated with a poorer prognosis in PCa [17–19,27]. Nevertheless, the 
impact of miR-205 as a potential prognostic outcome marker in PCa has not previously been investigated 
in a large complementary PCa collective until now. The HRPCa cohorts used in this study are a 
prerequisite for the validation and optimization of miR-based prediction of lymph node metastasis and 
cancer progression in PCa due to the relatively high rates of relevant events in this subgroup in 
comparison with low- or intermediate-risk series [10,32]. The primary aim of this study is to assess the 
validity of a miR-205-based prognostic tool using two well-characterized HRPCa cohorts. 
2. Results 
2.1. MiR-205 Is Under-Expressed and Its Reconstitution Leads to Proliferation—Inhibition in  
PCa Cells  
We analysed the expression of miR-205 in LNCaP and PC-3 cells via qRT-PCR and demonstrated 
that androgen-sensitive LNCaP cells showed a lower miR-205 expression than androgen-insensitive 
PC-3 cells (Figure 1A, p < 0.05). Transfection efficiency of the cell lines was verified using qRT-PCR 
(Figure 1B, p < 0.01). Proliferation assays in the cell lines showed that miR-205 transfection reduced 
cell proliferation significantly (Figure 1C, p ≤ 0.01). On day five post transfection 61% and 68% of 
LNCaP and PC-3 cells were viable. We then analysed whether the expression of miR-205 showed an 
impact on the invasive activities of the cells. Boyden chamber invasion assays revealed reduced 
invasion levels in PC-3 cells transfected with pre-miR-205 (Figure 1D). These results demonstrate that 
miR-205 acts as a tumour suppressor in PCa cells by regulating cell growth and invasiveness. 
2.2. MiR-205 Is Under-Expressed in a HRPCa and Shows Increasing Down-Regulation in  
Lymph Node Metastases  
To prove whether miR-205 is down-regulated in high-risk PCa cases, we subsequently analysed  
miR-205-expression in a HRPCa study collective (n = 105) and in BHP samples (n = 10) serving as 
controls. Clinical demographics of the study cohort and the BHPs are summarized in Table 1 and 
respectively in Table S1. In our study group mean miR-205 expression was significantly lower in the 
cancerous samples than in BPH controls. 98.1% of the tumour samples showed a lower miR-205 
expression compared with mean expression of BPH samples (p ≤ 0.01, comparing absolute ΔCt levels 
of individual samples to the mean ΔCt expression of 10 BPH samples). Using the ΔΔCt method we 
found that 82 of 105 cancer samples (78.1%) had a more than two-fold reduction in miR-205 
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expression if compared to the control tissue (p ≤ 0.01, see Figure S1). From these results we concluded 
that miR-205 is frequently and strongly reduced in HRPCa cases. 
Figure 1. (A) Boxplots of Real-Time polymerase chain reaction (PCR) assays in PCa cell 
lines LNCaP and PC-3 compared to benign hyperplastic prostate tissue (BPH, n = 10);  
(B) Histograms indicating transfection efficiency of transient miR-205. Transfection was 
verified by measuring miR-205 expression via Real-Time Quantitative PCR (qRT-PCR) in 
pre-miR-205 transfected cells compared to cells transfected with scrambled miRNA. Error 
bars represent the standard deviation of three independent experiments; (C) MTS 
proliferation assays in precursor-miR 205 transfected cell lines LNCaP and PC3. 
Histograms indicate the percentage of living cells compared with cells transfected with 
scrambled miRNA after transient transfection with pre-miR-205 (day 0) at given intervals 
(2 and 5 days); (D) MiR-205 up-regulation reduces cell migration of PCa cells. PC-3 cells 
were transfected with pre-miR-205 or scrambled miRNA. Migration of PC-3 cells was 
measured over 6 h in a Transwell
®
 cell culture chamber. Four chambers from three 
different experiments were analysed (p = 0.005). Error bars represent the standard 
deviation of three independent experiments. * indicates p < 0.01. p-values were calculated 
in cell lines and BPH tissue (A) using one-way ANOVA with post hoc testing  
(Tukey’s test). Student’s unpaired t-test was used for transfection efficiency and 
proliferation/invasion experiments (B–D).  
 
(A) (B) 
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Figure 1. Cont. 
 
(C) (D) 
Table 1. Preoperative and postoperative patients’ characteristics of the HRPCa study 
cohort (n = 105) and the HRPCa validation cohort (n = 78).  
 Study cohort Validation cohort 
Number of patients 105 78 
Median ΔCt miR-205 
expression (range) 
0.33 (−7.9–4.1) 1.96 (−4.95–5.0) 
Median follow-up,  
months (range) 
78.3 (1–154) 117 (14–173) 
Median Age, years (range) 65.9 (47–81) 63 (41–75) 
Median PSA, ng/µL (range) 32 (20–160) 14 (2.7–95.3) 
Gleason Score (GS): 
GS ≤ 6 2 (1.9%) 24 (30.4%) 
GS =7 31 (29.5%) 37 (46.8%) 
GS 8–10 72 (68.6%) 18 (22.8%) 
Pathological Stage (pT): 
pT 2 17 (17.2%) 24 (34.2%) 
pT3a 28 (26.7%) 35 (44.3%) 
pT3b 44 (41.9%) 16 (24.1%) 
pT4 16 (15.2%) 4 (5.1%) 
Nodal Status (LN): 
LN neg 64 (61.0%) 70 (89.7%) 
LN pos 41 (39.0%) 8 (10.3%) 
Relapse Events: 
Biochemical recurrence 38 (36.2%) 36 (49.4%) 
Clinical failure 24 (22.9%) 11 (13.9%) 
Cancer-specific mortality 11 (10.5%) 9 (11.4%) 
Any cause death 21 (20.0%) 16 (24.1%) 
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Next, we analysed the expression of miR-205 in lymph node metastasis. As shown in Figure 2A the 
expression of miR-205 in lymph node metastases (n = 11) was significantly and increasingly reduced 
when compared with the mean miR-205 expression in primary PCa samples of the study cohort  
(n = 105) and BPH controls (n = 10). Figure 2B shows miR-205 expression in primary tumours and 
corresponding synchronous lymph node metastases (n = 11). We found miR-205 to be down-regulated 
in all analysed pairs (p = 0.0001) and observed a more than two-fold down-regulation in 8 of the  
11 pairs (72.7%) indicating that lymph node metastases are characterized by a strong and increasing 
reduction of miR-205 expression when compared with the primary tumour. 
2.3. MiR-205 Expression Is Not Significantly Linked to Clinical Prognostic Parameters in HRPCa 
Based on the result that miR-205 is down-regulated in lymph node metastasis we suggested that 
progressive miR-205 down-regulation might be associated with clinical parameters in HRPCa. To 
correlate miR-205 down-regulation with advanced PCa stages, we related the clinical parameters of the 
HRPCa patients to corresponding miR-205 expression patterns.  
Figure 3 shows miR-205 expression in HRPCa cases separated by the respective clinical parameters 
in comparison with BPH. All clinical parameters show a significantly lower miR-205 expression in 
every stage compared to BPH tissue as control (p < 0.01). The pathological stage (p = 0.793), Gleason 
score (p = 0.956) and the nodal status (p = 0.31) of the primary tumour at surgery or high/low 
preoperative parameters (PSA-values, age at surgery) could not be stratified by miR-205 expression. 
2.4. MiR-205 as a Prognostic Factor in HRPCa 
To evaluate if miR-205 down-regulation might be prognostic in HRPCa we performed  
Kaplan–Meier estimates and Cox proportional hazard models. To stratify cut-off values for the optimal 
trade-off between specificity and sensitivity, Z-score normalised values of relative miR-205 expression 
in the specimen of the study group were dichotomised for CSM, BCR and CF using receiver operating 
characteristic (ROC) curves. AUC-values of the ROC curves ranged between 49.2% and 53.3%. 
(upper right plots, Figure 4A–C), indicating no discriminative value and very limited predictive power. 
Despite this, no significant difference could be found in miR-205 expression between the subgroups 
for all endpoints analysed (left plots, Figure 4A–C) and no correlation could be demonstrated between 
miR-205 down-regulation and CSM, CF or BCR using Cox regression analysis. Also, undichotomised 
values gave no significant results either (data not shown). Paradoxically however, in Kaplan–Meier 
estimates, up-regulation of miR-205 expression was associated with a worse prognostic outcome, but 
this trend only reached marginal significance for CSM and CF (middle plots, Figure 4A–C, CSM,  
p = 0.08; CF, p = 0.09; BCR, p = 0.12).  
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Figure 2. Increasing down-regulation of miR-205 expression in a HRPCa cohort (n = 105) 
and lymph node metastases. Relative miR-205 expression was analysed by the ΔCt method 
using qRT-PCR in all samples. (A) MiR-205 expression was analysed in 10 BPH tissues 
(left box), 105 HRPCa specimen (middle box) and 11 lymph node metastases (right box). 
Significant reductions in expression levels are marked by * (p <0.01). p-values were 
calculated using one-way ANOVA with post hoc testing (Tukey’s test); (B) Dot plot of  
miR-205 expression in synchronous lymph node metastasis. 11 pairs of primary tumour 
samples and corresponding lymph node metastases were analysed. p-value was calculated 
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Figure 3. MiR-205 expression as related to different clinical parameters in the study cohort 
(n = 105). Relative miR-205 expression was analysed in all samples by the ΔCt method 
using qRT-PCR. (A), (B) and (C) Boxplots showing the relation of miR-205 expression 
with the pathological tumour stage, Gleason score and the nodal status of the primary 
tumour in the study cohort in comparison to that in 10 BPH tissues. p-values were 
calculated using one-way ANOVA (A and B) and Student’s unpaired t-test (C). (D) and (E) 
Dot plots showing the association of miR-205 expression with preoperative PSA-values 
and age at surgery. 
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Figure 3. Cont.  
 
2.5. Down-Regulation of MiR-205 Fails as a Prognostic Factor in HRPCa  
To confirm the findings observed in the study cohort (n = 105), we analysed a complementary 
HRPCa-cohort (n = 78) after adjusting the mean of each sample’s miR-205 expression values to 0 and 
standard deviation to 1 by Z-score normalisation, thus improving comparability between cohorts. 
Clinical demographics of the validation cohort are summarized in Table 1. Z-scores of the validation 
cohort were dichotomised using the same thresholds as for the first cohort.  
D E 
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Figure 4. MiR-205 as a prognostic marker in a HRPCa study cohort (n = 105) for the clinical endpoints (A) Cancer-specific mortality (CSM); 
(B) Clinical failure (CF) and (C) Biochemical recurrence (BCR). Left plots: boxplots showing relative miR-205 expression (ΔCt sample) in 
patients with and without the indicated endpoints. Middle plots: Kaplan–Meier estimates in HRPCa patients with and without the respective 
endpoints. Patients were dichotomised by miR-205 expression according to optimal cut-off values for each endpoint calculated by ROC 
(upper right plots). p-values were calculated using log-rank test. Lower right tables: uni- and multivariate Cox-regression analysis regarding 
dichotomised miR-205 expression, Gleason score and combined pT score (pT2c/3a vs. pT3b/4) for the time to the respective end-points.  
p-values were calculated using Wald test.  
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Figure 4. Cont. 
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Figure 5. MiR-205 as a prognostic marker in a HRPCa validation cohort (n = 78) for clinical endpoints (A) cancer-specific mortality (CSM); 
(B) clinical failure (CF) and (C) biochemical recurrence (BCR). Left plots: boxplots showing relative miR-205 expression (ΔCt sample) in 
patients with and without the indicated endpoints. Middle plots: Kaplan–Meier estimates in HRPCa patients with and without the respective 
endpoints. Patients were dichotomised by miR-205 expression according to optimal cut-off values for each endpoint calculated by ROC (upper 
right plots). p-values were calculated using log-rank test. Lower right tables: uni- and multivariate Cox-regression analysis regarding 
dichotomised miR-205 expression, Gleason score and combined pT score (pT2c/3a vs. pT3b/4) for the time to the respective end-points.  
p-values were calculated using Wald test. 
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Figure 5. Cont. 
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We also found a significant down-regulation of miR-205 in the validation cohort (Figure S2). 78.2% 
(61 of 78 samples) of the tumour samples of the validation cohort were characterised by a more than  
two-fold reduction of miR-205 expression compared to mean expression in 10 BPH samples  
(p ≤ 0.01; Figure S1). As already shown in the study cohort we found no association of miR-205  
down-regulation with clinical parameters (p > 0.05, see Figure S3) or correlation of miR-205 expression to 
CSM, CF or BCR (Figure 5) using univariate Cox regression analysis.  
However, we confirmed the finding that miR-205 up-regulation (ΔCt > 0.75) was associated to 
reduced CSM in Kaplan–Meier analysis (p = 0.02). Multivariate analysis also confirmed that miR-205 
up-regulation was an independent predictor of CSM (p = 0.0003), but not for CF or BCR in the 
validation cohort.  
3. Discussion  
Emerging evidence shows that miRs not only impact upon physiologic development such as 
embryogenesis but also upon cancerogenesis, including PCa development [7]. Whilst numerous reports 
dwell on specific aberrant miR expression profiles, only limited information is available on the 
potential use of miRs as biomarkers and clinical prognosticators in PCa. Therefore, we analysed the 
expression of miR-205, previously reported to be dysregulated in cancer, in two well-characterized 
HRPCa series and in in vitro cell culture models.  
We found miR-205 to be significantly and frequently under-expressed in both analysed HRPCa 
cohorts and in PCa cell lines, indicating that down-regulation of miR-205 is a very common process in 
HRPCa. These findings are consistent with previous studies on miR-205 expression describing  
miR-205 as down-regulated in various types of cancer like prosate cancer, breast cancer or Barrett’s 
oesophagus [11–14,20–22]. Using PCa cell lines we demonstrated a tumour-suppressive function of 
miR-205 affecting cellular growth, adhesion and migration and confirmed earlier results that describe 
miR-205 as a tumour suppressor [17–19,23,27]. Moreover, three recent studies suggested that miR-205 
down-regulation might be associated with an adverse outcome in PCa patients [17,26,27]. The study 
by Hulf et al. showed that epigenetic-induced repression of miR-205 is associated with poorer 
prognosis in localized PCa cases. Tucci et al. demonstrated that p63 regulates the expression of  
miR-205 in PCa and revealed that defects in the p63/miR-205 axis correlate to a poorer outcome in 
PCa. Both studies were limited by the usage of biochemical recurrence as the main clinical endpoint, 
which has a lower prognostic relevance than clinical recurrence or cancer-specific mortality of the 
patients. Using tumour samples isolated from a TURP (transurethral resection of the prostate) cohort 
recruited in the pre-PSA era, the third study by Hagman et al. indicates that miR-205 down-regulation 
is associated with adverse outcome in PCa patients, thus potentially functioning as a prognostic marker 
in PCa. Nevertheless, none of these recent studies correlated miR-205 expression with cancer-specific 
mortality or clinical recurrence using a high-risk PCa cohort. Since the prognostic power of miR-205 
expression has not been previously determined in an untreated HRPCa cohort, we correlated miR-205 
expression to firm clinical endpoints using two well characterized HRPCa series serving as 
independent study and validation cohorts [10–32]. Contradictory to the observed association of 
biochemical relapse with loss of p63/miR-205 function or with epigenetic-induced repression of  
miR-205, we showed that strong down-regulation of miR-205 was not associated with CSM, CF, BCR 
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or clinical parameters in HRPCa patients. This result accords with miRNA expression studies showing 
that miR-205 does not correlate to outcome in PCa [11–14]. Even if our study is limited to the use of 
high-risk samples only, our analysis strongly implicates that down-regulation of miR-205 in primary 
PCa cases fails to function as an independent prognostic marker in PCa. Based on these results it will 
be of interest to analyse the potential of epigenetic-induced or p63-dependent down-regulation of  
miR-205 as a prognostic marker in HRPCa. 
In contrast to the expected progressive down-regulation of miR-205 in aggressive PCa cases, we 
even observed a moderate up-regulation of miR-205 in patients with higher risk for CSM and were 
able to confirm this result in a validation cohort suggesting potentially different roles of miR-205 in 
various PCa risk-groups. This paradoxical observation was backed by the finding that miR-205 
expression is significantly lower in the indolent, androgen-sensitive cell line LNCaP compared with 
the aggressive PC-3 cell line. This antithetic regulation of miR-205 in more aggressive PCa samples may 
seem paradoxical, but might be consistent with the observation that miR-mediated regulation of target 
molecules may be determined by the specific microcellular environment and dynamic regulation [33,34].  
Such an environmental determination for miR-205 seems perfectly possible, since several studies 
describe miR-205 as up-regulated in several cancer types like lung cancer or HNSCC (head and neck 
cell squamous carcinoma) [28,29]. An oncogenic role for miR-205 is supported by inhibition of 
tumour suppressors like PTEN, a gene frequently mutated in PCa, or SHIP2 [28–31]. Thus, miR-205 
might act as a tumour suppressor or an oncogene in different tissues and at different stages of tumour 
progression [11]. Such a pivotal role for miR-205 has been suggested in a recent review by Greene  
et al. looking at potential target genes of miR-205 [16]. Nevertheless, the relevance of the observed 
correlation between miR-205 up-regulation and a poorer outcome in PCa patients has to be questioned 
since the AUC values we found by ROC computation showed an average of around 50%. This result 
weakens the assumption that miR-205 up-regulation could predict CSM in either cohort reliably. We 
are planning to carry out further expression studies using enlarged high-risk patient cohorts to clarify 
the role of miR-205 up-regulation as predictor for CMS in various risk-groups of PCa.  
Several independent studies have shown that miR-205 was markedly down-regulated in cells that 
undergo ephitelial to mensynchymal transition (EMT) by targeting ZEB1, SIP1 or PKCe [23–27]. EMT 
is considered an essential process in tumour metastasis, suggesting that miR-205 down-regulation 
might be associated to metastasis in PCa. In this context it was recently reported that miR-205  
down-regulation is directly involved in the development of androgen independency in PCa cells and is 
correlated to the occurrence of metastases [17,19]. The last finding by Hagman et al. was demonstrated 
in transurethral-acquired localized tumour samples of castration-resistant PCa (CRPC) patients, who 
had received neoadjuvant hormonal or radiation therapy [17]. In contrast, we could not find 
progressive miR-205 down-regulation in primary cancers of patients with lymph node metastasis 
compared to patients with localised disease. However, all samples used in the present study were taken 
from patients with hormone naïve disease, who never received adjuvant therapy. Our finding that  
miR-205 expression in primary PCa cases is not associated with the occurrence of metastasis is 
confirmed by studies screening for metastasis-associated miRs. These studies showed no differences in 
miR-205 abundance between organ-confirmed tumours and those with extraprostatic disease  
extension [10,11,14]. Nevertheless, we observed strong and increasing down-regulation of miR-205 in 
a set of lymph node metastases if compared to the expression in corresponding primary tumour 
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samples. Depending on these results we concluded that down-regulation of miR-205 is critically 
involved in invasion, adhesion and homing of PCa cells after migration from the original location of 
the prostate to the exptraprostatic tissue. This notion is supported by our in vitro results showing that 
miR-205 regulates migration and adhesion of PCa cells independently from the proliferative activity of 
the cells. One explanation for the differential expression of miR-205 between the primary PCa and its 
lymph node metastasis might be the observed pivotal role of miR-205 as an ongogenic or  
tumour-suppressive miR. It might be critical for PCa cells to balance down-regulation of miR-205 
expression in the microenvironment of normal prostate tissue avoiding severe up-regulation of 
potential tumor-suppressive miR-205 target genes like PTEN or SHIP2. In contrast, metastatic cells 
undergoing EMT increase their cell mobility to migrate from the original location and to home to 
lymph nodes or other extraprostatic tissues. This process might be associated with strong and 
progressive down-regulation of miR-205 increasing the expression of oncogenes involved in EMT, 
like ZEB1 or SIP1 [14,23–26]. To prove this hypothesis, we are planning to elucidate the correlation of 
miR-205 to relevant target genes in primary PCa cases and its metastasis in the future.  
Overall, there is clear evidence that miR-205 acts as a tumour suppressor in PCa, interfering with 
processes involved in castration resistance and EMT [17,19,25]. Our present data promote a  
tumour-suppressive role of miR-205 in HRPCa due to its frequent down-regulation in tumourous 
tissue. Moreover, lymph node metastasis progressively down-regulate miR-205 in comparison to the 
primary tumour suggesting that miR-205 is critically involved in distinct processes leading to 
migration, invasion or homing of metastatic PCa cells. However, down-regulation of miR-205 clearly 
failed to act as a useful clinical predictor for progression or metastasis in HRPCa. Paradoxically, we 
found a tendency that miR-205 up-regulation correlates with adverse outcome of prostate cancer 
patients. Depending on pivotal functions of miR-205 in cancerogenesis we suggest that miR-205 
expression might be tightly controlled at different tumour stages affecting the expression of either 
tumour suppressors or oncogenes.  
4. Experimental Section  
4.1. Cell Lines 
LNCaP (androgen-sensitive) and PC-3 (androgen-independent) human prostate carcinoma cell lines 
were obtained from ATCC (American Type Culture Collection, Chicago, IL, USA) and cultured in 
RPMI 1640 (PAA, Pasching, Austria) supplemented with 10% fetal calf serum (FCS), 100 U/mL 
penicillin, 100 mg/L streptomycin and 2 mmol/L glutamine. 
4.2. Cell Transfection 
PC-3 and LNCaP cells were plated in a final concentration of 3 × 10
4
 to 5 × 10
4
 per well. After  
24 h, OPTI-MEM medium mixed with Lipofectamine 2000 and precursor-miR-205 or scrambled 
miRNA as control was applied to selected wells following the manufacturer’s protocol.  
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4.3. Cell Proliferation Assay 
PC-3 and LNCaP cells were plated at 3 × 10
4
 to 5 × 10
4
 per well in triplicate in 96-well plates.  
MiR-205 transfection was carried out after 24 h using the method described above. After 2 and 5 days, 
cells were analysed with MTS CellTiter96 Proliferation Assay (Promega, Madison, WI, USA, at  
490 nm with a monochromator (Biorad, Hercules, FL, USA) using the manufacturer’s protocol. 
4.4. In Vitro Invasion Assay 
A modified Boyden chamber assay was performed as described by Grunewald et al. [35]. PC-3 
cells were cultivated and transfected with pre-miR-205 or scrambled miRNA as described in 4.1. After 
48 h incubation and overnight starvation in DMEM plus 0.5% FCS, cells were seeded in the upper 
chamber of BSA-coated 8 μM pore size Transwell® Boyden chambers (Corning star, Cambridge, MA, 
USA). 10% FCS growth medium was added to the bottom chamber as an attractant and cells were 
allowed to migrate through the membrane for 6 h. After removal of all cells remaining at the upper 
surface using a cotton carrier the lower surfaces of the membranes were stained for 30 s in a solution 
of 1% (w/v) crystal violet. Membranes were then washed with distilled water. Cell-associated crystal 
violet was extracted in 10% acetic acid and measured at 595 nm absorbance. The experiments were 
performed in triplicate.  
4.5. Patients and Samples 
Men with HRPCa who had undergone radical retropubic prostatectomy (RRP) between 1987 and 
2005 at the Community Hospital of Karlsruhe, Germany and the Department of Urology and Pediatric 
Urology of the University Medical Center Würzburg, Germany (study cohort characterized previously 
by Spahn et al. [10]) and the University Hospital Leuven, Belgium (validation cohort) were identified 
in the European Clinical and Translational High-Risk Prostate Cancer Research Group database 
(EMPaCT) and included into this study. Our study cohort also included 11 patients of which we had 
access to samples of synchronous lymph node metastases. All RRP and lymph node metastasis samples 
were paraffin-embedded and areas with >90% cancerous tissue were selected; likewise prostate 
adenomectomy samples from the Department of Urology and Pediatric Urology of the University 
Medical Center, Würzburg were identified in a respective database and areas with >80% adenoid tissue 
were selected (for clinical demographics see Table S1). PCa specimens (whole mount sections, 4 mm 
intervals) were staged and graded according to the 2002 TNM classification and the Gleason grading 
system by two experienced uro-pathologists. All patients were pre-operatively subjected to digital rectal 
examination, transrectal ultrasound, assessment of PSA, CT and bone scan. None of the patients had 
received neoadjuvant hormonal-, radiation- or chemotherapy. Follow-up visits including digital rectal 
examination, transrectal ultrasound and assessment of PSA were scheduled every 3 months for the first 
2 years after RRP, every 6 months in the following 3 years, and annually thereafter. BCR was defined 
as PSA ≥ 0.2 ng/mL on two consecutive follow-up visits. CF was defined either as histologically 
proven local recurrence or distant metastasis confirmed by CT or bone-scan. Cause of death was 
verified by chart review and CSM was defined as death due to prostate cancer. Overall survival (OS) 
was defined as time from RRP to death from any cause, cancer-specific survival (CSS) as the time 
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from RRP to death attributed to PCa or complications of the disease. Clinical and pathological 
characteristics, BCR- and CF-free survival, CSM and OS were comparable for both cohorts (see Table 1 
and Figure S4). After a median follow-up of 78 months (1–154) for the study cohort and 117 months 
(14–173) for the validation cohort a total of 24 men (22.9%) and 11 men (13.9%) suffered CF and 11 
(10.5%) and 9 (11.4%) CSM, respectively. The estimated 10-year overall and cancer-specific survival 
rates were comparable for both patient groups (61.3% and 87.3% for the study cohort and 71.1% and 
81.5% for the validation cohort, see Figure S4). 
4.6. qRT-PCR 
Total RNA was extracted from PCa samples and BPH tissues with Total RNA Extraction Kit (Life 
Technoligies, Carlsbad, NM, USA). For cell lines, TRIzol Agent (Life Technoligies, Carlsbad, NM, 
USA) was applied 48 h after transfection and RNA was extracted and precipitated using Chloroform 
and Isopropanol. The RNA concentration was determined with a Bioanalyser (BIORAD, Hercules, FL, 
USA). cDNA was synthesized according to the TaqMan miR Assay protocol (Life Technoligies, 
Carlsbad, NM, USA). Mature miR expression was quantified in tissue samples with TaqManR miR 
assay kits and an Applied Biosystems 7900 HT system. We followed the protocol provided in the 
manufacture’s instructions (Applied Biosystems, Foster City, CA, USA). The expression of RNU6b 
was used for normalization. Relative miR expression was calculated with the comparative ΔCt-method 
(ΔCt sample = Ct sample − Ct RNU6b; ΔCt BPH = Ct BPH − Ct RNU6b). Fold changes were 
calculated using the ΔΔCt-method (ΔΔCt = fold change = 2(ΔCt Sample − ΔCt BPH)), whereas ΔCt BPH was 
determined as the mean of the ΔCt values of the 10 BPH samples. Calculations were carried out 
assuming equal RNA-concentrations and complete efficiancy of qRT-PCR. 
4.7. Statistical and Bioinformatical Analysis 
Statistical computation was achieved by using the statistical language R. Mean values of normally 
distributed data were compared with a two-sided unpaired student’s t test. More than two group means 
were differentiated by analysis of variance (ANOVA) with post hoc testing (Tukey’s test) if significant 
differences occurred. Various risk factors were correlated in uni- and multivariate Cox proportional 
hazard models to predict CSM, CF and BCR using the bioconductor package “survival.”  
Kaplan–Meier estimates were created using Z-score normalised and subsequently dichotomised data. 
For miR-205, optimal thresholds were calculated for dichotomisation by using the package  
“pROC.” (http://cran.r-project.org/web/packages/pROC/index.html). Significant associations were set  
as p < 0.01 (*). 
5. Conclusions  
We present our results of miR-205 expression in two of the largest HRPCa series reported to date 
serving as independent study and validation cohorts. Our present data promote a tumour-suppressive 
role of miR-205 in HRPCa due to its frequent and increasing down-regulation in tumourous tissue and 
in lymph node metastasis suggesting miR-205 to be critically involved in migration, invasion or 
homing of PCa cells. However, down-regulation of miR-205 clearly failed to act as a useful clinical 
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predictor for progression or metastasis in HRPCa. Moreover, we observed a tendency that miR-205  
up-regulation correlates with an adverse outcome for prostate cancer patients. These findings might 
have implications for the use of miR-205 as a prognostic marker and therapeutic target in PCa.  
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